Pendapatan operasional sadurunge ngurangi amortisasi: Vanda Pharma (VNDA)

The implementation of automated CNS molecule screening optimizes research, as confirmed by the monthly EBITDA trend, where the figure is recorded at 0.00. Growth is based on the patent protection of Hetlioz and strong pricing power within niche markets. The integration of precision neurotherapy into schizophrenia treatment standards creates an indispensable foundation for the business development of Vanda Pharmaceuticals (VNDA).

Bathi operasional EBITDA Vanda Pharmaceuticals (VNDA): kanggo periode 23.11.2025 - 11.11.2026

Ringkesan rincian data analitis Vanda Pharmaceuticals Inc. (VNDA)

- rega saham lan konsensus proyeksi valuasi:

Bagan kutipan Vanda|VNDA - Bagan rega target

- indikator kapitalisasi bursa perusahaan:

Kapitalisasi pasar Vanda Pharmaceuticals|VNDA - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data ekuitas miturut neraca:

Nilai Aset Bersih saben Saham Vanda Pharmaceuticals|VNDA - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih vandapharma.com|VNDA - Total Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

Rasio Kabeh Utang marang Dana Pribadi Vanda Pharmaceuticals|VNDA - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang modal Vanda Pharma|VNDA - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Vanda Pharmaceuticals|VNDA - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Vanda Pharmaceuticals|Rasio likuiditas darurat vandapharma.com

- rincian bathi lan kelipatan pasar:

VNDA - Bathi resik|Prakiraan bathi resik Vanda Pharmaceuticals|VNDA - Pangali P/E|Pangali Forward P/E vandapharma.com|VNDA - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Vanda Pharmaceuticals|VNDA - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben siji saham sajrone 12 wulan pungkasan Vanda Pharmaceuticals|VNDA - Bathi resik saben saham (EPS TTM)|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan vandapharma.com|VNDA - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Vanda Pharmaceuticals

Pambiji fundamental perusahaan:Vanda (VNDA)

This indicator measures the business's daily ability to generate cash flow from core operations, excluding non-cash asset depreciation expenses. For Vanda Pharmaceuticals (VNDA), whose developments are protected by a sovereign demand cycle, this underlying operational result before depreciation confirms the company's resilience as a defensive asset, reflecting the real efficiency of drug commercialization without the influence of macroeconomic fluctuations.

Karo sapa Vanda Pharmaceuticals saingan

ALKS (Alkermes Corp) - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|AVDL - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Pendapatan operasional sadurunge ngurangi amortisasi atai.life ATAI|GHRS (GH Research) - Bathi operasional sadurunge ngurangi amortisasi|Bathi sadurunge bunga, pajak, lan amortisasi Mind Medicine (MindMed) Inc. (MNMD)|CMPS (Compass Pathways) - Bathi operasional EBITDA|Bathi operasional sadurunge ngurangi amortisasi LB Corp (LBRX)|Bathi operasional EBITDA DRUG|CYBN (cybin.com) - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Alto Neuroscience ANRO|NRx Pharmaceuticals Inc. (NRXP) - Bathi sadurunge bunga, pajak, lan amortisasi|CING: Bathi operasional sadurunge ngurangi amortisasi|SILO: Bathi sadurunge mbayar bunga, pajak, lan amortisasi|CPHI: Bathi operasional EBITDA|clearmindmedicine.com (CMND) - Bathi operasional EBITDA|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Psyence Biomedical|Bathi operasional sadurunge amortisasi SPRC (SciSparc Ltd.)|Bathi operasional EBITDA SEEL|virpaxpharma.com - Bathi operasional sadurunge amortisasi|Bathi operasional EBITDA KRTX (Karuna Therapeutics)